Phase iii clinical clinical trials phase ii as topic. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Organisms1

Diseases47

Lung Neoplasms Neoplasms Neoplasm Metastasis Carcinoma, Non-Small-Cell Lung Disease Progression Breast Neoplasms Neutropenia Neoplasm Recurrence, Local Nausea Leukopenia Colorectal Neoplasms Recurrence Vomiting Drug-Related Side Effects and Adverse Reactions Melanoma Thrombocytopenia Brain Neoplasms Ovarian Neoplasms Prostatic Neoplasms Hematologic Diseases Carcinoma, Small Cell Kidney Neoplasms Carcinoma, Squamous Cell Stomach Neoplasms Head and Neck Neoplasms Carcinoma, Renal Cell Pancreatic Neoplasms Peritoneal Neoplasms Fatigue Diarrhea Carcinoma Stomatitis Adenocarcinoma HIV Infections Stroke Liver Neoplasms Acute Disease Pain Sarcoma Glioblastoma Lymphoma, Non-Hodgkin Bone Neoplasms Anemia Urologic Neoplasms Biliary Tract Neoplasms Multiple Myeloma Small Cell Lung Carcinoma

Chemicals and Drugs82

Antineoplastic Agents Deoxycytidine Cisplatin Fluorouracil Paclitaxel Taxoids Placebos Antibodies, Monoclonal, Humanized Carboplatin Vinblastine Organoplatinum Compounds Antineoplastic Agents, Phytogenic Antimetabolites, Antineoplastic Camptothecin Leucovorin Doxorubicin Antibodies, Monoclonal Cyclophosphamide Quinazolines Drugs, Investigational Dacarbazine Etoposide Epirubicin Vincristine Antineoplastic Agents, Alkylating Niacinamide Phenylurea Compounds Benzenesulfonates Angiogenesis Inhibitors Ifosfamide Tegafur Drug Combinations Methotrexate Oxonic Acid Prednisone Pyrroles Protein Kinase Inhibitors Thiophenes Recombinant Proteins Epothilones Mitomycin Tumor Markers, Biological Cancer Vaccines Anthracyclines Pyridines Interferon-alpha Thalidomide Antineoplastic Agents, Hormonal Platinum Compounds Antibiotics, Antineoplastic Guanine Indoles Pyrimidines Pyrazines Granulocyte Colony-Stimulating Factor Megestrol Acetate Bridged Compounds Antibodies, Monoclonal, Murine-Derived Triazoles Piperazines Biological Markers Boronic Acids Polyethylene Glycols Glutamates Benzamides Immunologic Factors Tamoxifen Estramustine Motilin Antithrombin III Anticarcinogenic Agents RNA Polymerase III Receptor, Epidermal Growth Factor Prostate-Specific Antigen Receptor, erbB-2 Androstenols Piperidines Nitriles Immunosuppressive Agents Sulfonamides Quinolines NAD(P)H Dehydrogenase (Quinone)

Analytical, Diagnostic and Therapeutic Techniques and Equipment77

Clinical Trials, Phase III as Topic Clinical Trials as Topic Clinical Trials, Phase II as Topic Treatment Outcome Antineoplastic Combined Chemotherapy Protocols Drug Administration Schedule Double-Blind Method Research Design Disease-Free Survival Clinical Trials, Phase I as Topic Randomized Controlled Trials as Topic Survival Analysis Infusions, Intravenous Placebos Combined Modality Therapy Survival Rate Multicenter Studies as Topic Controlled Clinical Trials as Topic Patient Selection Administration, Oral Neoplasm Staging Prospective Studies Follow-Up Studies Drug Evaluation Endpoint Determination Clinical Trials, Phase IV as Topic Chemotherapy, Adjuvant Kaplan-Meier Estimate Maximum Tolerated Dose Clinical Protocols Sample Size Early Termination of Clinical Trials Drug Therapy, Combination Prognosis Single-Blind Method Pilot Projects Remission Induction Feasibility Studies Treatment Failure Salvage Therapy Neoadjuvant Therapy Severity of Illness Index Risk Assessment Risk Factors Radiotherapy, Adjuvant Questionnaires Drug Approval Proportional Hazards Models Reproducibility of Results Meta-Analysis as Topic Immunotherapy Dose Fractionation Injections, Subcutaneous Molecular Targeted Therapy Retrospective Studies Injections, Intravenous Data Interpretation, Statistical Random Allocation Cross-Over Studies Area Under Curve Chemoradiotherapy Statistics, Nonparametric Multivariate Analysis Palliative Care Predictive Value of Tests Probability Pain Measurement Analysis of Variance Drug Evaluation, Preclinical Induction Chemotherapy Phytotherapy Models, Statistical Radiotherapy Cohort Studies Karnofsky Performance Status Therapies, Investigational Maintenance Chemotherapy

Psychiatry and Psychology2

Patient Compliance Pain

Phenomena and Processes9

Metabolic Detoxication, Phase II Time Factors Dose-Response Relationship, Drug Maximum Tolerated Dose Drug Resistance, Neoplasm Myoelectric Complex, Migrating Area Under Curve Probability Pain

Disciplines and Occupations5

Research Design Evidence-Based Medicine Medical Oncology Biomedical Research Outcome Assessment (Health Care)

Anthropology, Education, Sociology and Social Phenomena8

Quality of Life Drug Approval National Cancer Institute (U.S.)Patient Education as Topic United States Food and Drug Administration Survival Informed Consent National Institutes of Health (U.S.)

Technology, Industry, Agriculture3

Drug Industry Dietary Supplements Polyethylene Glycols

Humanities1

Quality of Life

Information Science8

Survival Rate Periodicals as Topic Questionnaires Review Literature as Topic Data Interpretation, Statistical Abstracting and Indexing as Topic Textbooks as Topic Terminology as Topic

Named Groups1

Research Subjects

Health Care68

Clinical Trials, Phase III as Topic Clinical Trials as Topic Clinical Trials, Phase II as Topic Treatment Outcome Double-Blind Method Disease-Free Survival Clinical Trials, Phase I as Topic Randomized Controlled Trials as Topic Survival Analysis Survival Rate Multicenter Studies as Topic Controlled Clinical Trials as Topic Patient Selection Prospective Studies Follow-Up Studies Clinical Trials, Phase IV as Topic Kaplan-Meier Estimate Clinical Protocols Sample Size Early Termination of Clinical Trials Single-Blind Method Pilot Projects Feasibility Studies Clinical Trials Data Monitoring Committees Treatment Failure Severity of Illness Index Congresses as Topic Risk Assessment Risk Factors Safety Cost-Benefit Analysis Guidelines as Topic Questionnaires Outcome Assessment (Health Care)Proportional Hazards Models Reproducibility of Results Meta-Analysis as Topic Practice Guidelines as Topic Patient Compliance National Cancer Institute (U.S.)Patient Education as Topic Retrospective Studies Data Interpretation, Statistical United States Food and Drug Administration Random Allocation Cross-Over Studies Area Under Curve Statistics, Nonparametric Multivariate Analysis Palliative Care Predictive Value of Tests Probability Analysis of Variance Informed Consent National Institutes of Health (U.S.)Research Support as Topic Societies, Medical Age Factors International Agencies Intention to Treat Analysis Models, Statistical Placebo Effect Patient Participation Cohort Studies Patient Satisfaction Benchmarking Karnofsky Performance Status Bias (Epidemiology)

Publication Characteristics1

Clinical Trial, Phase III

Geographicals3

United States Europe Japan

Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Psychiatry and Psychology Phenomena and Processes Disciplines and Occupations Anthropology, Education, Sociology and Social Phenomena Technology, Industry, Agriculture Humanities Information Science Named Groups Health Care Publication Characteristics Geographicals

Clinical Trials, Phase III as Topic Clinical Trials as Topic Clinical Trials, Phase II as Topic Treatment Outcome Antineoplastic Combined Chemotherapy Protocols Drug Administration Schedule Antineoplastic Agents Double-Blind Method Research Design Disease-Free Survival Clinical Trials, Phase I as Topic Randomized Controlled Trials as Topic Deoxycytidine Survival Analysis Cisplatin Infusions, Intravenous Fluorouracil Metabolic Detoxication, Phase II Paclitaxel Taxoids Lung Neoplasms Placebos Combined Modality Therapy Time Factors Survival Rate Neoplasms Multicenter Studies as Topic Controlled Clinical Trials as Topic Patient Selection Antibodies, Monoclonal, Humanized Administration, Oral Neoplasm Staging Prospective Studies Dose-Response Relationship, Drug Follow-Up Studies Carboplatin Drug Evaluation Endpoint Determination Neoplasm Metastasis Carcinoma, Non-Small-Cell Lung Disease Progression Clinical Trials, Phase IV as Topic Vinblastine Organoplatinum Compounds Quality of Life Breast Neoplasms Chemotherapy, Adjuvant Antineoplastic Agents, Phytogenic Antimetabolites, Antineoplastic Camptothecin Kaplan-Meier Estimate Leucovorin Doxorubicin Neutropenia Neoplasm Recurrence, Local Antibodies, Monoclonal Maximum Tolerated Dose Nausea Clinical Protocols Sample Size Cyclophosphamide Early Termination of Clinical Trials Drug Therapy, Combination Prognosis Single-Blind Method Quinazolines Drugs, Investigational Leukopenia United States Colorectal Neoplasms Dacarbazine Pilot Projects Evidence-Based Medicine Remission Induction Etoposide Epirubicin Medical Oncology Feasibility Studies Clinical Trials Data Monitoring Committees Treatment Failure Salvage Therapy Recurrence Vincristine Neoadjuvant Therapy Antineoplastic Agents, Alkylating Periodicals as Topic Severity of Illness Index Niacinamide Congresses as Topic Phenylurea Compounds Benzenesulfonates Vomiting Drug-Related Side Effects and Adverse Reactions Angiogenesis Inhibitors Risk Assessment Melanoma Ifosfamide Drug Resistance, Neoplasm Thrombocytopenia Brain Neoplasms

No FAQ available that match "phase iii clinical clinical trials phase ii as topic"